Hydralazine in Clinical Practice
Primary Indications
Hydralazine combined with isosorbide dinitrate is indicated as scheduled therapy for self-identified African American patients with NYHA class III-IV heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal therapy with ACE inhibitors (or ARBs), beta-blockers, and mineralocorticoid receptor antagonists. 1
Heart Failure with Reduced Ejection Fraction
For African American patients with HFrEF: The combination of hydralazine and isosorbide dinitrate provides a 43% relative reduction in all-cause mortality and a 33-39% reduction in heart failure hospitalizations when added to guideline-directed medical therapy 1, 2, 3
For non-African American patients with HFrEF: Hydralazine-isosorbide dinitrate may be considered in patients who cannot tolerate ACE inhibitors, ARBs, or ARNIs due to drug intolerance, hypotension, or renal insufficiency, though the evidence is weaker in this population 1, 4
Critical caveat: Hydralazine should NOT be used as monotherapy in heart failure—this is associated with harm (Class III recommendation) 4
Hypertension
Hydralazine may be considered as a fifth-line agent for resistant hypertension, but MUST be combined with a beta-blocker and diuretic to counteract reflex tachycardia and sodium retention 4
Contraindicated as monotherapy for chronic hypertension due to reflex sympathetic activation 4
Dosing Regimens
Oral Dosing for Heart Failure
Starting dose: Hydralazine 37.5 mg three times daily combined with isosorbide dinitrate 20 mg three times daily 1, 2
Target dose: Hydralazine 75 mg three times daily combined with isosorbide dinitrate 40 mg three times daily 1, 2
Titration schedule: Increase every 2-3 weeks as tolerated, monitoring blood pressure, heart rate, and renal function 2
Critical point: The mortality benefit demonstrated in clinical trials was only achieved at these higher doses with three-times-daily dosing—lower doses or less frequent administration have not shown the same benefit 4
Mean doses achieved in clinical trials: approximately 175 mg hydralazine and 90 mg isosorbide dinitrate daily (divided into three doses) 1
Intravenous Dosing for Hypertensive Emergencies
Initial dose: 10-20 mg slow IV bolus, repeated every 4-6 hours as needed 5
Usual dose range: 20-40 mg per dose 5
Blood pressure begins to decrease within 10-30 minutes, with maximal effect at 10-80 minutes 5
Duration of action: 2-4 hours 4
Important limitation: Hydralazine is NOT a first-line agent for most acute hypertensive emergencies due to unpredictable blood pressure response and prolonged duration of action 4
Patients with marked renal damage may require lower doses 5
Most patients can be transitioned to oral therapy within 24-48 hours 5
Dosing Considerations for Hypertension
Total daily doses should be less than 150 mg to avoid drug-induced systemic lupus erythematosus 4
Must be combined with beta-blocker and diuretic therapy 4
Absolute Contraindications
Hydralazine is contraindicated in the following conditions: 6
Hypersensitivity to hydralazine 6
Coronary artery disease 6
Mitral valvular rheumatic heart disease 6
Advanced aortic stenosis (due to unpredictable blood pressure effects) 4
Adverse Effects
Common Side Effects
Headache (most common, usually improves with continued therapy) 1, 7
Gastrointestinal complaints (nausea, vomiting, diarrhea) 1
Reflex tachycardia (requires concurrent beta-blocker therapy) 4, 8
Serious Adverse Effects
Drug-induced lupus-like syndrome (arthralgia, fever, rash)—risk increases with doses >150 mg/day and prolonged use 4, 2, 6
Blood dyscrasias: Hemolytic anemia, leukopenia, agranulocytosis, purpura 6
Peripheral neuritis: Paresthesia, numbness, tingling (may require pyridoxine supplementation) 6
Myocardial ischemia and infarction: Myocardial stimulation can precipitate anginal attacks and ECG changes 6
Vasculitis and glomerulonephritis 9
Cardiovascular Effects
Reflex tachycardia and increased ejection velocity (attenuated in heart failure patients) 8
Sodium and water retention (requires concurrent diuretic therapy) 4
May increase pulmonary artery pressure in patients with mitral valvular disease 6
May reduce pressor responses to epinephrine 6
Monitoring Recommendations
Initial Monitoring (First 3 Months)
At 2-3 days after initiation: 2
- Renal function (serum creatinine, estimated GFR)
- Electrolytes (particularly potassium)
Monthly during titration: 2
- Blood pressure and heart rate at every visit
- Renal function and electrolytes
- Assessment for orthostatic hypotension
Hold or reduce dose if: 2
- Systolic BP <100 mmHg or diastolic BP <60 mmHg
- Heart rate >110 bpm
- Significant rise in serum creatinine
Ongoing Monitoring (Every 3 Months)
Blood pressure and heart rate 2
Renal function and electrolytes 2
Complete blood count and antinuclear antibody (ANA) titer, even if asymptomatic 6
Screen for signs of drug-induced lupus: arthralgia, fever, chest pain, continued malaise, rash 2, 6
Special Monitoring Situations
If patient develops unexplained symptoms: 6
- Complete blood count
- ANA titer
- Assessment for lupus-like syndrome
If positive ANA titer: Carefully weigh risks versus benefits of continuing therapy 6
If blood dyscrasias develop: Discontinue therapy immediately 6
Drug Interactions
Major Interactions
MAO inhibitors: Use with caution; may potentiate hypotensive effects 6
Diazoxide: Profound hypotensive episodes may occur when used concomitantly; continuous observation required for several hours 6
Other potent parenteral antihypertensives: Monitor closely for excessive blood pressure reduction 6
Food Interactions
- Administration with food results in higher plasma levels 6
Special Populations and Clinical Contexts
Patients with Renal Insufficiency
Hydralazine-isosorbide dinitrate may be considered in patients intolerant of ACE inhibitors or ARBs due to renal insufficiency 1
Use with caution in patients with advanced renal damage 6
Lower doses may be required 5
Evidence of increased renal blood flow and maintained glomerular filtration rate in hypertensive patients with normal kidneys 6
Patients with Low Baseline Blood Pressure
Low systolic blood pressure should NOT be considered a contraindication to hydralazine-isosorbide dinitrate in heart failure patients 10
In the A-HeFT trial, patients with baseline systolic BP ≤126 mmHg had similar relative benefit from treatment as those with higher BP 10
Hydralazine-isosorbide dinitrate did not reduce systolic BP in patients with low baseline BP (<126 mmHg) 10
Pregnancy
Pregnancy Category C 6
Teratogenic in mice at 20-30 times the maximum human dose and possibly in rabbits at 10-15 times the maximum human dose 6
Teratogenic effects include cleft palate and malformations of facial and cranial bones 6
Patients with Coronary Artery Disease
Absolute contraindication due to risk of myocardial ischemia and infarction 6
Myocardial stimulation can precipitate anginal attacks 6
Patients with Cerebrovascular Disease
Use with caution in patients with cerebrovascular accidents 6
Lowering blood pressure may increase cerebral ischemia in cases of increased intracranial pressure 5
Integration with Guideline-Directed Medical Therapy
Sequencing in Heart Failure Treatment
Step 1 (First-line agents): 1
- ACE inhibitors or ARBs (or ARNIs)
- Beta-blockers
- Mineralocorticoid receptor antagonists
- SGLT2 inhibitors
Step 2 (For African American patients with persistent NYHA class III-IV symptoms): 1
- Add hydralazine-isosorbide dinitrate to existing therapy
Alternative use (For patients intolerant of first-line agents): 1
- Consider hydralazine-isosorbide dinitrate as substitute therapy
- Referral to heart failure specialist recommended for guidance 1
Insufficient Data Scenarios
Concomitant use with ARNIs: There are insufficient data to guide the use of hydralazine-isosorbide dinitrate with sacubitril/valsartan 1
Non-African American patients with mild heart failure: Not studied 3
Common Pitfalls and How to Avoid Them
Adherence Challenges
Three-times-daily dosing is associated with poor adherence due to complexity and side effects 1, 2
Prescription refill rates are very low even when prescribed 1
Solution: Emphasize the documented 43% mortality reduction to improve compliance; counsel patients that headache and dizziness typically improve with continued therapy 2, 7
Inadequate Dosing
Many patients in clinical practice receive lower doses than those proven effective in trials 1
Solution: Titrate to target doses of hydralazine 75 mg and isosorbide dinitrate 40 mg three times daily as tolerated 1, 2
Monotherapy Use
Never use hydralazine alone in heart failure—this is harmful 4
Never use hydralazine without beta-blocker and diuretic in hypertension 4
Solution: Always combine with isosorbide dinitrate for heart failure; always combine with beta-blocker and diuretic for hypertension 4
Nitrate Tolerance
Nitrate tolerance can develop with continuous use 1
Solution: Combination with hydralazine helps prevent nitrate tolerance 1; ensure nitrate-free interval of at least 10 hours if using nitrates alone 1
Failure to Monitor for Lupus-Like Syndrome
Risk increases with prolonged use and doses >150 mg/day 4, 6
Solution: Monitor ANA titers and screen for symptoms (arthralgia, fever, rash) at regular intervals 2, 6
Premature Discontinuation Due to Side Effects
Headache and gastrointestinal complaints are common but often improve with continued therapy 1, 7
Solution: Counsel patients about expected side effects and their tendency to resolve; consider slower titration if side effects are limiting 2
Economic Value
Economic analysis from A-HeFT demonstrated that hydralazine-isosorbide dinitrate increases survival while reducing healthcare costs 1
Cost per life-year gained: <$60,000, classified as high-value therapy 1
Particularly cost-effective in developing countries where newer agents may be prohibitively expensive 9